p=0.001). SAVR was an independent predictor of moderate-severe PPM (HR 1.80 95% CI 1.25-2.59, p=0.002) as was increased BMI (HR 1.14 per 1kg/m2 increase in BMI), pre-exiting hypertension (HR 2.09) and the use of smaller valve sizes (HR 29.06 for valve sizes 18-23mm). TAVR however was not a predictor of moderate-severe PPM. Inhospital mortality was 3.9% in TAVR versus 6.1% in SAVR group (p=0.171). Two-year outcomes including allcause and cardiovascular mortality, and readmissions were similar in both groups (log rank p>0.05 for all comparisons). Predictors of all-cause 2-year mortality differed between groups although low baseline haemoglobin and post procedure stage 2-3 acute kidney injury were predictors following both SAVR and TAVR. Moderate-severe PPM however, was a predictor of all-cause 2-year mortality after SAVR (HR 1.78; 95% CI 1.10-2.88, p=0.018), but not after TAVR (p=0.737). Conclusions SAVR and TAVR offer similar mid-term outcomes in MO patients with severe AS, however, TAVR offers advantages in terms of periprocedural morbidity and reduced incidence of moderate-severe patient prosthesis mismatch.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.